Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Blood Typing01:10

Blood Typing

Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Obexelimab for the Treatment of IgG4-Related Disease.

The New England journal of medicine·2026
Same author

Secukinumab for Giant Cell Arteritis.

NEJM evidence·2026
Same author

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

The New England journal of medicine·2026
Same author

Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease.

Annals of the rheumatic diseases·2026
Same author

Evaluation of steroid toxicity using the Glucocorticoid Toxicity Index-Metabolic Domains instrument in adults with myasthenia gravis: a real-world study in the USA.

Journal of comparative effectiveness research·2026
Same author

Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.

Rheumatology and therapy·2026

相关实验视频

Updated: May 29, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

结晶球蛋白质的病变

Manuel Ramos-Casals1, John H Stone, Maria C Cid

  • 1Josep Font Laboratory of Autoimmune Diseases, Institut Clínic de Medicina I Dermatologia, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.

Lancet (London, England)
|August 27, 2011
PubMed
概括

低温球蛋白是蛋白质,在低温下聚集在一起,导致器官损伤. 治疗侧重于根本原因,组合疗法显示出有前途.

科学领域:

  • 免疫学 免疫学 免疫学
  • 类风湿病学 类风湿病学
  • 腎臟病學 (nephrology) 是一種醫學專業.

背景情况:

  • 低温球蛋白是沉低于37°C的免疫球蛋白.
  • 它们通过血管污泥或免疫介导机制引起器官损伤.
  • 低球蛋白血症与感染 (例如,C型肝炎),自身免疫性疾病和恶性瘤有关.

研究的目的:

  • 定义低温球蛋白及其相关综合征.
  • 概述混合球蛋白血综合征的诊断标准.
  • 讨论临床表现,预后和治疗策略.

主要方法:

  • 关于冷球蛋白血症和冷球蛋白血型血管炎的文献综述.
  • 诊断途径和临床表现的分析.
  • 对各种治疗方法的治疗结果的评估.

主要成果:

  • 混合结晶球蛋白性综合征需要器官参与和循环结晶球蛋白.
  • 皮肤紫外线是最常见的症状;周围神经,脏和关节经常受到影响.
  • 预后取决于器官损伤和并发症;超过90%的病例有可识别的原因.

结论:

更多相关视频

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

相关实验视频

Last Updated: May 29, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

  • 治疗应针对冷球蛋白血症的根本原因.
  • 联合或连续的抗病毒疗法和向生物治疗可能比单一疗法更有效.
  • 对最佳治疗策略的进一步研究是有必要的.